Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF by Triantafillidou, Christina et al.
RESEARCH Open Access
Medical Research Council dyspnea scale does not
relate to fibroblast foci profusion in IPF
Christina Triantafillidou
1, Effrosyni D Manali
1,2, Christina Magkou
3, Christina Sotiropoulou




3 and Spyros A Papiris
1*
Abstract
Background: In Idiopathic pulmonary fibrosis (IPF) irreversibly progressive fibrosing parenchymal damage, leads to
defects in mechanics and gas exchange, manifesting with disabling exertional dyspnea. Previous studies have
shown a relationship between fibroblast foci (FF) profusion and severity and survival and a relationship between
dyspnea grade and severity and outcome. We hypothesized a relationship between Medical Research Council
(MRC) dyspnea scale with FF, and a relationship between FF and functional parameters and survival.
Methods: We retrospectively reviewed 24 histologically documented IPF patients. Profusion of FF was
semiquantitatively evaluated by two scores, Brompton and Michigan. Survival analysis was performed by fitting Cox
regression models to examine the relationship of the two scores with survival and the non-parametric Spearman
correlation coefficient was calculated to describe the relationships of FF scores with dyspnea scores and functional
parameters.
Results: No statistically significant correlation between FF scores and the MRC scores was observed (p = 0.96 and
p = 0.508 respectively). No significant correlation between FF scores and survival (p = 0.438 and p = 0.861
respectively) or any functional parameter was observed.
Conclusions: The lack of relationship between the MRC dyspnea scale and the FF might relate to the fact that
dyspnea in IPF better reflects the overall of lung damage and its related consequences on mechanics and gas
exchange whereas FF, one of its histological hallmarks, may not reflect its entire histology derangement also
constrained by the geographically limited sampled tissue. This might be also valid for the observed lack of
association between FF and survival or functional parameters.
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Background
Idiopathic Pulmonary fibrosis (IPF) is a dreadful and
incurable, chronic and irreversibly progressive fibrosing
lung disease [1]. Inflammation and fibrosis constitute
the mainstay of parenchymal lung damage. Progression
of lung damage leads to defects in mechanics and gas
exchange and clinically manifests with progressive exer-
tional dyspnea leading to disability, ending to death.
The diagnostic histopathologic features of usual inter-
stitial pneumonia (UIP) consist at low-magnification
view of a patchwork pattern of lung involvement with
honeycomb areas alternating with normal lung and par-
enchymal scarring and at higher magnification of
inflammation overshadowed by fibrosis and polyclonal
fibroblastic aggregates called fibroblast foci (FF) coexist-
ing with areas of inactive collagen-type scarring [2].
Fibroblast foci are considered foci of active, currently
ongoing interstitial fibrosis. The above histological pat-
tern is valuable for diagnosis in the non typical cases
since according to several studies the diagnosis of UIP/
IPF can be made with confidence based on clinical and
roentgenographic findings in the most (typical) cases
[1,3-5].
The clinician caring for IPF patients necessitates non-
invasive, simple, reliable and reproducible parameters to
estimate the severity, progression and prognosis of the
* Correspondence: papiris@otenet.gr
12nd Pulmonary Department, “Attikon” University Hospital, Athens Medical
School, National and Kapodistrian University of Athens, Greece
Full list of author information is available at the end of the article
Triantafillidou et al. Diagnostic Pathology 2011, 6:28
http://www.diagnosticpathology.org/content/6/1/28
© 2011 Triantafillidou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.disease. Regarding clinical parameters, several studies
have shown that different scores of exertional dyspnea
constitute a reliable tool which serves the function
described above [6-11]. This is also the case for func-
tional parameters such as the total lung capacity (TLC),
the forced vital capacity (FVC), the carbon monoxide
diffusing capacity (DLCO) [12,13] and their deteriora-
tion over time [14], the desaturation and the distance
walked during the six-minute walk test [15,16] and the
PaO2-slope and the maximal oxygen uptake during car-
diopulmonary exercise testing [17,18]. Last but not least
among the non-invasive parameters evaluating IPF is the
extent of fibrosis on high-resolution computed tomogra-
phy scans [6,19].
Further studies examining the relationship between
histopathology and survival of patients with IPF, have
highlighted the potential role of the profusion of FF as
predictor of survival in IPF patients. However, results
have been controversial so far with investigators con-
cluding either “pro” or “con” their prognostic signifi-
cance [20-24,24-26]. Although progressive dyspnea is
the most prominent symptom in UIP/IPF patients, the
relationship between dyspnea and histopathologic fea-
tures of disease such as fibroblastic foci, is not studied.
In this study we hypothesized a relationship between
the Medical Research Council (MRC) chronic dyspnea
scale and the FF profusion in surgical lung biopsies
from UIP/IPF patients at diagnosis, as well as a relation-




This study was approved by the “Scientific Board-IRB-
Committee of Bioethics, Attikon University Hospital
Athens Greece”, National and Kapodistrian University of
Athens. Patients fulfilling the criteria of the American
Thoracic Society and European Respiratory Society for
the diagnosis of IPF [27] and the histological pattern of
UIP on surgical lung biopsy obtained through open
thoracotomy or video-assisted thoracoscopy performed
from February 1998 through December 2006 were
included retrospectively (clinical information was
obtained from medical records). Αll patients were treat-
ment naive when surgical lung biopsy was performed.
Secondary causes of lung fibrosis were excluded: none
of the patients had a history of environmental or occu-
pational exposure, drug toxicity or autoimmune rheu-
matic disease, as documented by history, clinical and
immunological tests. Survival time was calculated from
t h et i m eo fs u r g i c a ll u n gb i o p s yu n t i lt h e i rd e a t ho r
time of verification of vital status, which was ascertained
by follow-up with the subjects directly, their families or
personal physicians.
Dyspnea
Dyspnea was assessed at diagnosis by the treating physi-
cians using the modified MRC chronic dyspnea self-
administered questionnaire consisting of six questions
about perceived breathlessness: 0, no dyspnea; 1, slight
dyspnea (shortness of breath when hurrying on the level
or walking up a slight hill); 2, moderate dyspnea (walks
slower than people of the same age on the level because
of breathlessness); 3, moderately severe dyspnea (stops
because of breathlessness when walking at own pace on
the level); 4, severe dyspnea (stops for breath after walk-
ing about 100 yards or after a few minutes on the level);
5, very severe dyspnea (too breathless to leave the house
or breathless when dressing or undressing) [7].
Pulmonary Functional Tests (PFTs)
PFTs were done at diagnosisa ta ni n t e r v a ln o tm o r e
than a month prior to biopsy. PFTs included forced
expiratory volume during the first second of expiration
(FEV1), forced vital capacity (FVC), total lung capacity
(TLC), and single-breath carbon monoxide diffusing
capacity (DLCO) all measured by MasterScreen Body
apparatus (Erich Jaeger GmbH, Wuerzburg, Germany).
Measurements are expressed as absolute values and as
percent of predicted normal.
Pathologic assessment
Lung specimens were obtained from at least two lobes of
the same lung, when technically feasible. All slides were
reviewed separately and without knowledge of the clinical
data by two independent pathologists (CM, DR). Both
pathologists were unaware of the clinical and functional
characteristics of the patients. Patients whose histopatho-
logic findings were not consistent with UIP were
excluded. Ten randomly selected non-overlapping fields
stained with hematoxylin-eosin were viewed at low-
power magnification (x40) and scored semiquantitatively
for profusion of FF (Figure 1) by two different score
systems: the Brompton score, using a 0-6 scale (0 repre-
sents an absence of FF, while a 6 or more FF in the exam-
ined field is scored as 6) and the Michigan score, using a
0-3 scale (0: absent, 1: mild, 2: moderate, 3: marked) as
Figure 1 High magnification view stained with hematoxylin-
eosin showing areas of fibroblast foci (arrows).
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from two different sites, an average score was calculated.
To evaluate the lymphocyte CD8 subpopulation lung tis-
sues were stained with mouse monoclonal antibodies
anti-pan-T cell (anti CD3; dilution, 1:200) and anti CD8
(dilution 1:40) [Dako; Glostrup, Denmark] according to
the labelled streptavidin-biotin complex method. The
sections were deparaffinized and rehydrated with Tris-
buffered saline solution (0.005 mmol/L Tris and
0.15 mmol/L NaCl; pH, 7.6) for 10 min. Endogenous per-
oxidase was blocked with 3% hydrogen peroxide for
5 min. Then the sections were washed in Tris-buffered
saline solution and incubated with primary antibodies at
appropriate dilutions for 1 h. Biotinylated antimouse IgG
was used as a secondary antibody (Dako), followed by
peroxidase-conjugated streptavidin (Dako). The peroxi-
dase reaction was developed using 3,3’-diaminebezidine
tetrachloride (0.25 mg dissolved in 1 mL of 0.02% hydro-
gen peroxide) for 3 min. The results were expressed as
the percentage of nuclear immunopositive surface in
relation to the total nuclear surface of infiltrative cells
within the tissue.
Statistical analysis
Data are presented as mean ± SD or median (range)
values. Mean values of FF scores of the two observers
were used in the statistical analysis. Inter-rater agree-
ment was estimated by the weighted kappa statistic. The
non-parametric Spearman correlation coefficient was
calculated to describe the relationships of Brompton and
Michigan scores with the other examined variables.
Survival analysis was also performed by fitting Cox
regression models to examine the relationship of the
two scores and MRC with survival. The Kaplan-Meier
method was used to estimate survival distribution. The
two scores and the MRC were also divided into two
groups using their median value and comparison of
their survival distributions were made by the log-rank
test. Statistical analysis was performed by the Statistical
Package for the Social Sciences Software Version 11.0
(SPSS, Chicago, IL).
Results
The population studied consisted of 24 patients with
clinical, radiological and pathological features of IPF. The
demographic, clinical, and functional characteristics of
the study population at the time of diagnosis are given in
Table 1. Eleven patients were female and thirteen were
male with a mean age of 63.5 ± 7 years. Half of the
patients were no smokers, the rest being ex-smokers. All
patients were treatment naïve at the time of surgical
biopsy. After entry into the study, 18 patients received
treatment with immunosuppressive or cytotoxic therapy
(low dose prednisolone alone or in combination with
azathioprine, or mycophenolate mofetil or colchicine,
withdrawn and not substituted at first sign of opportunis-
tic infection from the lungs or other organs), while 6
patients never received any treatment. Nine patients had
an MRC score of 1, ten a score of 2, three a score of 3
a n dt w oas c o r eo f4 .N op a t i e n ti n c l u d e di nt h es t u d y
had an MRC score of 5. The results of the PFTs are
shown in Table 1. All patients had a restrictive pattern
with a mean value for FEV1/FVC ratio of 88 ± 5.6%, for
TLC% of 61.7 ± 11.7% and 43.6 ± 14.4% for DLCO%.
Multiple biopsies were performed in the majority of
patients (18 out of 24, 75%). The profusion of FF in lung
biopsy specimens according to the Brompton and Michi-
gan scores was found at a median value of 2,2 and 1,46
respectively (Table 2).
At the time of reporting of this study, eight patients
had succumbed to IPF while sixteen patients were still
alive (Figure 2). Follow-up time ranged from 2 months
to 8.08 years. Median survi v a lw a s7 8m o n t h s( 9 5 %C I
43.66-112.34). All deaths were directly attributable to
the disease, a fact verified by death certificates. Interob-
server agreement for histopathologic scores was substan-
tial for both scoring systems (Brompton score Weighted
Kappa = 0.6, Michigan score Weighted Kappa = 0.7).
No significant correlation was found between both
Brompton or Michigan score and the MRC dyspnea
score (r = -0.348, p = 0.96 for Brompton score, r =
-0.142, p = 0.508 for Michigan score) (Table 3).
Table 1 Demographic, clinical and functional data of the
study population (n = 24)
Age, year (mean ± SD) 63.5 ± 7
Sex (M/F) 13/11
Alive/Dead 16/8
Smoking history (n %)
Ex smokers 12 (50%)
No smokers 12 (50%)
Current smokers 0 (0%)







PFTs (mean ± SD)
FEV1 - FEV1 % pr 1,97 ± 0,4 - 83,7 ± 15,9%
FVC - FVC % pr 2,25 ± 0,6 - 76,2 ± 15,2%
FEV1/FVC (ratio) % pr 88 ± 5,6%
TLC - TLC % pr 3,31 ± 0,7 - 61,7 ± 11,7
DLCO - DLCO % pr 3,23 ± 1,2 - 43,6 ± 14,4%
M/F Male/Female, FEV1 Forced expiratory volume at 1 second, % per cent,
FVC Forced vital capacity, TLC Total Lung Capacity, DLCO Diffusion capacity
for carbon monoxide, FEV1/FVC: FEV1/FVC ratio.
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ted between FF scores (both Brompton and Michigan
score) and survival (Cox regression results: a) Brompton
score: RR = 1.234, p = 0.438, 95% CI = 0.725-2.102,
b) Michigan score: RR = 1.102, p = 0.861, 95% CI =
0.372-3.269, or any of the other examined variables of
the pulmonary function tests (Table 3). However, the
MRC dyspnea score was found significantly correlated
with survival (RR = 2.283, p-value = 0.020, 95% CI:
1.137-4.582, n = 24). Kaplan-Meier curves for MRC and
FF scores are shown in Figure 3 and OR with CIs were
as follows: OR for MRC: group 0-2, group 3-5: p =
0.17, OR = 4.2, 95% CI = 0.535-32.956, OR for Bromp-
ton score group 1-2, group 3-5: p = 0.5, OR = 1.8, 95%
CI = 0.290-11.161, ΟR for Michigan score: group 0-1,
group 2-3: p = 1, OR = 1, 95% CI = 0.173-5.772.
As CD8 was another histopathologic feature of IPF
biopsies found to correlate with MRC in recent studies
of our group [7], the correlation of tissue CD8 with
both MRC scale and survival was examined with no sta-
tistically significant relationships found: (r = 0.154, p =
0.555, RR = 1.03, p = 0.42, 95% CI = 0.95-1.11, n = 17
respectively)
Discussion
In this study we hypothesized a relationship between the
MRC chronic dyspnea scale and the FF profusion scores
in surgical lung biopsies from UIP/IPF patients at diag-
nosis, to the best of our knowledge for the first time. In
addition we hypothesized a relationship between FF and
functional parameters of disease severity and survival in
our population studied. No statistically significant corre-
lation between FF scores and the MRC score was
observed. No significant correlation between FF scores
and functional parameters of disease severity as well as
survival was documented.
Previous studies have shown that the MRC scale, a
non-invasive and simple clinical tool to estimate chronic
dyspnea, is reliable in the estimation of the severity, pro-
gression and prognosis in IPF patients [7,8,10]. Further-
more, previous studies of our group detected also a
relationship between the MRC scale and tissue infiltrat-
ing CD8+ T lymphocytes as well as CD8+ T lympho-
cytes recovered by bronchoalveolar lavage [28,29] as
well as a relationship between the MRC dyspnea and
physiological parameters obtained during maximal and
submaximal exercise testing known to reflect exercise
Table 2 The profusion of fibroblast foci according to two
different scales (N = 24)








Brompton score Median 2,2 Range (1, 5)





Michigan score Median 1,5 Range (1, 3)
Figure 2 The cumulative Kaplan-Meier survival plot. Survival of
24 patients with histologically documented UIP/IPF, followed till
death (uncensored: n = 8) or reporting of the study (censored: n =
16). Shown are sample size (n) and survival [mean and median (95%
Confidence Interval)].
Table 3 Relationships between the fibroblast foci scores
and the other examined parameters in the study
population (N = 24)
Variables Brompton score Michigan score
mMRC r -0.348 -0.142
p-value 0.096 0.508
FEV1 % r 0.122 -0.086
p-value 0.570 0.688
FVC % r 0.010 -0.157
p-value 0.964 0.463
FEV1/FVC % r 0.172 0.063
p-value 0.422 0.770
TLC % r -0.170 -0.118
p-value 0.426 0.584
DLCO % r 0.205 0.090
p-value 0.337 0.676
The non-parametric Spearman correlation coefficient was used. FEV1 Forced
expiratory volume at 1 second, % per cent, FVC Forced vital capacity, TLC
Total Lung Capacity, DLCO Diffusion capacity for carbon monoxide, FEV1/FVC:
FEV1/FVC ratio.
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Therefore, we assumed that the MRC score could also
be related with the FF profusion score in IPF lung biop-
sies, which has been shown predictive of survival in pre-
vious studies [20,21,23,24]. Nevertheless, the results of
the current study do not support our hypothesis of a
relation between this histopathologic characteristic of
IPF and the degree of dyspnea.
To the best of our knowledge there is only one study
examining the relationship between worsening dyspnea
over time (6 months) and the FF profusion in pharma-
cologically treated UIP/IPF patients that apparently
contradicts our results [25]. However, in this study
Collard and co-workers used a different dyspnea scale
e x t e n d i n gf r o m0( n od y s p n e a )t o2 0( d y s p n e aa tr e s t )
and the relationship between dyspnea and the FF profu-
sion at initial evaluation of patients and before treat-
ment initiation is not reported.
Regarding our second endpoint, no significant associa-
tion was found between survival and the profusion of FF
in surgical lung biopsies from patients with IPF, mea-
sured semiquantitatively by the two already described
score systems: the Brompton and the Michigan score
[21,22]. Published studies show contradictory results: in
agreement to our results, Flaherty and co-workers did
not find the profusion of FF to be a significant predictor
of survival for 99 patients with UIP by any method (the
Michigan score, the Brompton score and the Denver
score). Accordingly, Collard and co-workers did not find
a relationship between survival and any individual histo-
pathological feature, including the profusion of FF [25].
Similarly, in a recent work Hanak and co-workers failed
to detect any relationship between FF prevalence and
survival in IPF patients [26]. In contrast to the above,
other investigators succeeded to detect a relationship
between different methodologically obtained scores for
the estimation of the FF profusion and survival
[20,21,23,24].
As far as the association between the profusion of FF
and functional parameters is concerned, our results are
similar to the ones of Enomoto and co-workers [23].
The investigators who found a relationship between the
extent of FF and functional parameters mostly examined
changes of functional parameters over time such as the
decrease in both DLCO and FVC measured at 6 and
12 months after biopsy [21] and the worsening in per-
cent predicted FVC over 6 months of follow up [25].
That is, the profusion of FF was not correlated with the
initial pulmonary function status, but with their dete-
rioration over time.
In order to explain these contradictory results, one
notices following a critical and comparative analysis of
reported studies differences that mainly concern the
length of survival and the methods of assessing the FF
profusion [23-26]. Indeed, median survival ranges
between studies from 28.8 months [26] to 69 months
[24] and to 78 months in the present one, and the scor-
ing systems of profusion of FF are different between
study groups varying from the semiquantitative methods
including the Brompton, Denver, and the Michigan
scores [20-22,25] to more sophisticated quantitative
methods based on measurements with analytic software
[23,24,26].
Our explanation for the absence of a relationship of
FF profusion and indices of severity and survival
observed in this study might first relate to the fact that
Figure 3 Twenty four patients with histologically documented
UIP/IPF were followed till death (uncensored n = 8) or
reporting of the study (censored n = 16). (A) Kaplan-Meier
survival curve for MRC is shown. Patients with higher MRC scores
experienced shorter survival (p = 0.009). Kaplan-Meier survival curves
for both Brompton (B) and Michigan (C) scores are shown. No
significant correlation was found between the two subgroups and
survival.
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pathogenetic role, of all the histopathologic characteris-
tics of UIP/IPF, and [2,31] secondly, to the fact that the
geographically limited (small tissue size) of the lung
sampled may not necessary reflect the resultant of the
histopathology derangement in individual cases. Conse-
quently, the potential role of FF, sites of dynamic
ongoing active injury in a chronic progressive interstitial
lung disease as UIP/IPF is, [32] may better reflect the
previously observed relationship with indexes of disease
deterioration such as decrease of DLCO and FVC
[21,25] and dyspnea worsening [25].
On the other hand, progressive breathlessness, the
most disabling symptom of IPF though multifactorial
better reflects the overall of lung damage and its related
consequences on lung mechanics and gas exchange [33].
Thus, the finding of this study that the MRC dyspnea
scale does not correlate with FF profusion could be
explained by the fact that the defects in lung mechanics
and gas exchange which manifest clinically with progres-
sive exertional dyspnea might result from the entire
combination of histological changes that characterize
UIP/IPF and their geographical extension. Indeed, dys-
pnea scores are better shown to relate with histological
parameters such as end-stage fibrosis and honeycombing
[7,11].
The major weakness of the present study is its rela-
tively small number of patients and its retrospective
design. However, it includes a homogeneous population
of one academic department and its retrospective design
is a valid approach for the study of a disease with low
prevalence such as UIP/IPF. Prospective studies require
very long period of observation. In addition, the survival
rate of our patients is higher than that of patients
included in other studies and this might relate: firstly to
the very early stage disease of patients included as
shown by the fact that 19 of them presented MRC score
1 and 2 and no patient with MRC 5 was included, due
to the inability to perform lung biopsy in such severely
ill patients, and secondly to the fact that most patients
were treatment naïve or discontinued treatment on the
first sign of infection. Regarding this ultimate it is well
known that UIP/IPF is unresponsive to any immunosup-
pressive therapy which on the contrary leads unavoid-
ably to severe and often terminal infective complications
[34].
Conclusions
In conclusion, the missing relationship between the
MRC dyspnea scale and the FF profusion could be
explained with the fact that dyspnea in IPF better
reflects the overall of lung damage and its related conse-
quences on lung mechanics and gas exchange. FF, only
one of its histological hallmarks, might not reflect its
entire histology derangement also constrained by the
geographically limited sampled lung tissue. This might
be also valid for the observed lack of association
between FF and survival or functional parameters.
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